Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics Inc. (LCTX) is a clinical-stage biotechnology leader developing novel cell-based therapies for degenerative diseases. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research progress, and regulatory milestones.
Access authoritative information about LCTX's innovative platforms in cell replacement therapies and targeted drug delivery systems. Our curated collection features press releases covering clinical trial results, strategic partnerships, intellectual property updates, and scientific presentations.
Stay informed about advancements in treatments for retinal degeneration, spinal cord injuries, and oncology applications. All content is verified at source, ensuring reliable tracking of the company's progress in regenerative medicine. Bookmark this page for streamlined access to essential updates impacting LCTX's position in the biotech sector.
Lineage Cell Therapeutics (LCTX) presented data from its Phase 1/2a study of OpRegen, a cell therapy for geographic atrophy (GA) due to age-related macular degeneration (AMD), at the 2022 ARVO Annual Meeting. The 12-month primary endpoint data indicate OpRegen is well-tolerated, showing an acceptable safety profile. Preliminary improvements in visual function were noted in Cohort 4 patients with GA, with an average 7.6 letter gain in visual acuity. These findings support further development of OpRegen as a potential treatment for GA, previously thought to have no effective interventions.
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a fireside chat with CEO Brian M. Culley scheduled for April 27, 2022, at 3:30 PM EST. The event will be hosted by Mayank Mamtani, Senior Analyst at B. Riley Securities, focusing on two new cell therapy programs stemming from the collaboration with Roche and Genentech for the RG6501 (OpRegen®) program.
Lineage specializes in developing allogeneic cell therapies, targeting unmet medical needs in significant markets.
Lineage Cell Therapeutics (LCTX) announced a new development program for photoreceptor neural cell (PNC) transplants aimed at treating vision loss due to photoreceptor dysfunction. The company has filed for intellectual property protection regarding PNC manufacturing methods and demonstrated feasibility for large-scale production of photoreceptors. This initiative comes following a significant alliance with Roche and Genentech worth up to $670 million. Lineage aims to leverage its technology platform for clinical and commercial advancements in cell therapies.
Lineage Cell Therapeutics (LCTX) announced that Cancer Research UK has completed patient enrollment in the Phase 1 clinical trial for VAC2, an allogeneic cancer vaccine designed for non-small cell lung cancer (NSCLC). Lineage has now taken over responsibility for further clinical development of VAC2. Initial clinical results are expected later this year. Lineage's manufacturing improvements aim to prepare VAC2 for future trials, including an Investigational New Drug Application submission to the FDA. This step underlines their commitment to advancing innovative cancer therapies.
Lineage Cell Therapeutics, a clinical-stage biotech company, announced CEO Brian M. Culley will present at NobleCon18, on April 20, 2022, at 4:30 PM ET. The conference will be held at the Hard Rock Hotel & Casino in Hollywood, Florida, from April 19-21. Lineage specializes in allogeneic cell therapies aimed at significant medical needs, with products like OpRegen for macular degeneration and OPC1 for spinal cord injuries. An archived webcast of the presentation will be available from April 21 on the Lineage website.
Lineage Cell Therapeutics, Inc. (LCTX) will present at the 2022 Virtual Growth Conference on March 28, 2022, at 10 AM ET. CEO Brian M. Culley will participate in an Ophthalmology Panel and provide a corporate overview available on demand from the same date. The event, hosted by Maxim Group LLC and M-Vest, requires registration for participation. Lineage focuses on developing allogeneic cell therapies for unmet needs, including therapies for dry age-related macular degeneration and acute spinal cord injuries, with substantial market opportunities.
Lineage Cell Therapeutics (LCTX) has expanded its cell therapy pipeline to include an investigational auditory neuronal cell transplant aimed at treating hearing loss, particularly auditory neuropathy spectrum disorders. The company has filed for intellectual property to support this initiative, which addresses a significant global health issue affecting over 430 million people. CEO Brian Culley highlighted the potential benefits of auditory neuronal transplants and emphasized the efficient development process using existing infrastructure. The initiative follows a recent partnership with Roche and Genentech worth up to $670 million.
Lineage Cell Therapeutics (LCTX) reported full results from a Phase 1/2a clinical study of RG6501 (OpRegen®) for dry age-related macular degeneration (AMD). The therapy is developed in collaboration with Roche and Genentech. Results will be presented at the 2022 ARVO Annual Meeting. The study involved 24 patients across four cohorts, assessing safety and efficacy. No new treatment emergent adverse events were reported, indicating OpRegen has been well tolerated. Currently, there are no FDA or EMA approved treatments for dry AMD, highlighting the potential for OpRegen in a significant market.
Lineage Cell Therapeutics (LCTX) announced an exclusive worldwide collaboration with Roche and Genentech for the development of OpRegen, a retinal cell therapy, valued at up to $670 million. This partnership underscores the validation of Lineage's technology platform. In Q4 2021, total revenues increased to $1.2 million from $0.4 million in 2020, primarily from royalties and licensing fees. However, operating expenses surged to $29.2 million due to OpRegen-related costs, leading to a net loss of $29 million for the quarter. Lineage held $55.7 million in cash and equivalents as of December 31, 2021.
Lineage Cell Therapeutics, Inc. (LCTX) will release its Q4 and full-year 2021 financial results on March 10, 2022, after market close. A conference call will be held on the same day at 4:30 PM ET to discuss these results and provide a business update. LCTX focuses on developing allogeneic cell therapies targeting unmet medical needs, including treatments for age-related macular degeneration and spinal cord injuries. Investors can access the call by phone or via a live webcast on the company’s website.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
